Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593030 · ClinicalTrials.gov registry record
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
A clinical trial of Atrial Fibrillation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 220,518
- Enrollment target
- 1
- Study location
NCT04593030: Completed study of Atrial Fibrillation, sponsored by Brigham and Women's Hospital.
NCT04593030 is a study of Atrial Fibrillation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 220,518 participants, above the 1,905-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (11476% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04593030, a study of Atrial Fibrillation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 220,518 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Relative hazard of composite outcome of Stroke and Systemic Embolism - Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Warfarin
Study Locations (1)
Massachusetts
- Brigham And Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220,518 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-02-18 |
What the finished NCT04593030 record still lists
NCT04593030 is an observational study that tracks outcomes without assigning an intervention. Its 220,518 participants enrollment target places it among the larger protocols in the corpus, above the 1,905-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (11476% higher).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.
NCT04593030 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04593030 about?
NCT04593030 is a clinical study titled "Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04593030?
This trial is currently completed. The enrollment target is 220,518 participants. The study started on 2020-09-01. Estimated completion is 2021-02-18.
What conditions does trial NCT04593030 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04593030?
The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).
Who is sponsoring clinical trial NCT04593030?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04593030 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04593030's enrollment target sits among peer trials
220,518 1st of 202 higher than 202 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI